{"id":54403,"date":"2023-03-01T22:04:20","date_gmt":"2023-03-01T21:04:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/"},"modified":"2023-03-01T22:04:20","modified_gmt":"2023-03-01T21:04:20","slug":"rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/","title":{"rendered":"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference"},"content":{"rendered":"
\n

CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc.<\/a> (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in the Genetic Medicines Corporate Panel at the 43rd Annual Cowen Health Care Conference taking place in Boston, MA on Monday, March 6, 2023 at 10:30 a.m. ET.\n<\/p>\n

<\/a><\/p>\n

\nA live audio webcast of the presentation will be available under \u201cEvents\u201d in the Investors section of the Company\u2019s website at https:\/\/ir.rocketpharma.com\/<\/a>. The webcast replay will be available on the Rocket website following the conference.\n<\/p>\n

\nAbout Rocket Pharmaceuticals, Inc.<\/b>\n<\/p>\n

\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. The Company\u2019s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LV) based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket\u2019s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. Rocket also has preclinical AAV-based gene therapy programs in PKP2-arrhythmogenic cardiomyopathy (ACM) and BAG3-associated dilated cardiomyopathy (DCM). For more information about Rocket, please visit www.rocketpharma.com<\/a>.\n<\/p>\n

\nRocket Cautionary Statement Regarding Forward-Looking Statements<\/b>\n<\/p>\n

\nVarious statements in this release concerning Rocket\u2019s future expectations, plans and prospects, including without limitation, Rocket\u2019s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket\u2019s ongoing and planned clinical trials, the expected timing and outcome of Rocket\u2019s regulatory interactions and planned submissions, Rocket\u2019s plans for the advancement of its Danon Disease program, including its planned pivotal trial, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as \u201caim,\u201d \u201canticipate,\u201d “believe,” \u201ccan,\u201d \u201ccontinue,\u201d \u201cdesign,\u201d \u201cestimate,\u201d “expect,” “intend,” \u201cmay,\u201d “plan,” \u201cpotential,\u201d “will give,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket\u2019s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket\u2019s ongoing trials, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, our ability to submit regulatory filings with the U.S. Food and Drug Administration (FDA) and to obtain and maintain FDA or other regulatory authority approval of our product candidates, Rocket\u2019s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, our competitors\u2019 activities, including decisions as to the timing of competing product launches, pricing and discounting, our integration of an acquired business, which involves a number of risks, including the possibility that the integration process could result in the loss of key employees, the disruption of our ongoing business, or inconsistencies in standards, controls, procedures, or policies, our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire and any unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, filed February 28, 2023 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Kevin Giordano
\n
kgiordano@rocketpharma.com<\/a><\/p>\n

Investors<\/b>
Brooks Rahmer
\n
investors@rocketpharma.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in the Genetic Medicines Corporate Panel at the 43rd Annual Cowen Health Care Conference … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54403","6":"format-standard","7":"category-industry"},"yoast_head":"\nRocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in the Genetic Medicines Corporate Panel at the 43rd Annual Cowen Health Care Conference ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-01T21:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230301006098\/en\/1151092\/21\/Rocket_Pharma.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference\",\"datePublished\":\"2023-03-01T21:04:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/\"},\"wordCount\":852,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230301006098\\\/en\\\/1151092\\\/21\\\/Rocket_Pharma.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/\",\"name\":\"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230301006098\\\/en\\\/1151092\\\/21\\\/Rocket_Pharma.jpg\",\"datePublished\":\"2023-03-01T21:04:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230301006098\\\/en\\\/1151092\\\/21\\\/Rocket_Pharma.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230301006098\\\/en\\\/1151092\\\/21\\\/Rocket_Pharma.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/","og_locale":"en_US","og_type":"article","og_title":"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference - Pharma Trend","og_description":"CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in the Genetic Medicines Corporate Panel at the 43rd Annual Cowen Health Care Conference ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-01T21:04:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230301006098\/en\/1151092\/21\/Rocket_Pharma.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference","datePublished":"2023-03-01T21:04:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/"},"wordCount":852,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230301006098\/en\/1151092\/21\/Rocket_Pharma.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/","url":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/","name":"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230301006098\/en\/1151092\/21\/Rocket_Pharma.jpg","datePublished":"2023-03-01T21:04:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230301006098\/en\/1151092\/21\/Rocket_Pharma.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230301006098\/en\/1151092\/21\/Rocket_Pharma.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rocket-pharmaceuticals-to-participate-in-the-43rd-annual-cowen-health-care-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54403"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54403\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}